Back to results
US 2024/0191193 A1Published application
Method for ex-vivo expansion of regulatory t cells with enhanced suppressive function for clinical application in immune mediated diseases
AssigneeMallinckrodt Pharmaceuticals Ireland Limited
InventorsTinghua Cao, Li Li
Life of this patent
Estimating the term…
Abstract
The invention provides methods for the ex-vivo expansion of CD4+CD25+ Tregs. The invention provides a method for producing ex vivo expanded Tregs that may be used to inhibit unwanted human immune responses against self-antigens or allergens. Additionally, the ex vivo expanded Tregs may provide treatment for inflammatory/autoimmune diseases.
Claims12
A method of preparing a population of cells, the method comprising:
- a) obtaining a population of T cells from an individual with an immune-mediated disease selected from Systemic Lupus Erythematous, Multiple Sclerosis, asthma, Rheumatoid Arthritis, Crohn's Disease, or Ulcerative Colitis;
- b) isolating and purifying from the T cell population a subpopulation of CD4+CD25+ Tregs;
- and
- c) expanding the Treg cells of the subpopulation over 1,000 fold, in the presence of IL-2, anti-CD3 antibodies, and anti-CD28 antibodies, wherein the expanded Treg cells exhibit enhanced suppressive activity compared to a population of freshly purified, unexpanded Tregs from the individual;
- wherein the anti-CD3 antibodies and anti-CD28 antibodies are immobilized on a three-dimensional solid surface.
2 more elements
Dependencies are inferred from the claim text.